Back to Search
Start Over
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia
- Source :
- Antimicrob Agents Chemother
- Publication Year :
- 2020
- Publisher :
- American Society for Microbiology, 2020.
-
Abstract
- Cefepime-enmetazobactam is a novel β-lactam–β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae. This agent is being developed for a range of serious hospital infections. An understanding of the extent of partitioning of β-lactam–β-lactamase inhibitor combinations into the human lung is required to better understand the potential role of cefepime-enmetazobactam for the treatment of nosocomial pneumonia. A total of 20 healthy volunteers were used to study the intrapulmonary pharmacokinetics of a regimen of 2 g cefepime-1 g enmetazobactam every 8 h intravenously (2 g/1 g q8h i.v.). Each volunteer contributed multiple plasma samples and a single epithelial lining fluid (ELF) sample, obtained by bronchoalveolar lavage. Concentrations of cefepime and enmetazobactam were quantified using liquid chromatography-tandem mass spectrometry. The pharmacokinetic data were modeled using a population methodology, and Monte Carlo simulations were performed to assess the attainment of pharmacodynamic targets defined in preclinical models. The concentration-time profiles of both agents in plasma and ELF were similar. The mean ± standard deviation percentage of partitioning of total drug concentrations of cefepime and enmetazobactam between plasma and ELF was 60.59% ± 28.62% and 53.03% ± 21.05%, respectively. Using pharmacodynamic targets for cefepime of greater than the MIC and free enmetazobactam concentrations of >2 mg/liter in ELF of 20% of the dosing interval, a regimen of cefepime-enmetazobactam of 2 g/0.5 g q8h i.v. infused over 2 h resulted in a probability of target attainment of ≥90% for Enterobacteriaceae with cefepime-enmetazobactam MICs of ≤8 mg/liter. This result provides a rationale to further consider cefepime-enmetazobactam for the treatment of nosocomial pneumonia caused by multidrug-resistant Enterobacteriaceae.
- Subjects :
- 0301 basic medicine
Cefepime
030106 microbiology
Population
Microbial Sensitivity Tests
Pharmacology
wc_202
030226 pharmacology & pharmacy
03 medical and health sciences
0302 clinical medicine
Pharmacokinetics
medicine
Humans
Pharmacology (medical)
education
Volunteer
education.field_of_study
Cross Infection
qv_350.5.c3
medicine.diagnostic_test
business.industry
Healthcare-Associated Pneumonia
Triazoles
medicine.disease
Anti-Bacterial Agents
Cephalosporins
Regimen
Pneumonia
Infectious Diseases
Bronchoalveolar lavage
Pharmacodynamics
business
Azabicyclo Compounds
Monte Carlo Method
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 00664804
- Database :
- OpenAIRE
- Journal :
- Antimicrob Agents Chemother
- Accession number :
- edsair.doi.dedup.....8ae8a67db76cbb4b0e5e516757a2125f